OSU 6162

06/01/2022 - "(-)-OSU6162 improved fatigue, as measured with the FSS score, significantly in patients with complete RTW. "
06/01/2022 - "The dopaminergic regulator (-)-OSU6162 has shown promising results regarding the mitigation of fatigue in various neurological diseases, and therefore the authors aimed to investigate the efficacy of (-)-OSU6162 in alleviating fatigue and other sequelae after aSAH. "
01/01/2021 - "(-)-OSU6162 is well tolerated in ME/CFS patients and shows promise as a novel treatment to mitigate fatigue and improve mood and health-related quality of life in ME/CFS. "
06/01/2022 - "A double-blind, randomized, placebo-controlled, single-center trial was performed in which 96 participants with post-aSAH fatigue were administered 30-60 mg/day of (-)-OSU6162 or placebo over a period of 12 weeks. "
06/01/2022 - "Fatigue and other sequelae after aSAH were similarly alleviated by treatment with (-)-OSU6162 and placebo. "

12/01/2018 - "In view of its good tolerability, (-)-OSU6162 may offer a new treatment option for alleviating mental fatigue, as well as depression, in MS. Larger, randomized double-blind controlled trials are warranted to confirm the present preliminary observations."
03/01/2017 - "The effects of (-)-OSU6162 at a dose of 15 mg twice a day were evaluated using self-assessment scales and neuropsychological tests measuring mental fatigue. "
03/01/2017 - "Treatment with (-)-OSU6162 had no significant effect on mental fatigue in patients with traumatic brain injury compared with placebo."
03/01/2017 - "To examine the effects of the monoaminergic stabilizer (-)-OSU6162 on mental fatigue in patients with traumatic brain injury. "
06/01/2018 - "The monoaminergic stabiliser (-)-OSU6162 has in previous studies shown promising effects on mental fatigue after stroke and traumatic brain injury. "

02/02/2001 - "We have evaluated, in this study, the effect of (-)-OSU6162, on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a primate model of Parkinson's disease. "
02/02/2001 - "Our data suggests that (-)-OSU6162 could be of significant clinical value to reduce L-DOPA-induced dyskinesias in fluctuating advanced Parkinson's disease patients."
07/28/1997 - "Our investigation suggests that (-)-OSU 6162 may be useful an an adjuvant treatment to levodopa in advanced Parkinson's disease to selectively combat levodopa-induced dyskinesias without affecting the antiparkinsonian response."
07/28/1997 - "(-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease."
02/02/2001 - "Co-administration of (-)-OSU6162 with L-DOPA/benserazide produced a significant reduction in L-DOPA-induced dyskinesias. "

01/01/2019 - "In conclusion, our results provide further support for OSU6162 as a novel treatment for alcohol use disorder. "
12/01/2015 - "Thus a larger placebo-controlled efficacyclinical trial is needed to further investigate the potential of OSU6162 as a novel medication for alcohol dependence. "
01/01/2014 - "The role of dopamine, for example, by using the dopamine stabilizer (-)-OSU6162, in alcohol dependence will be revised. "
01/01/2018 - "The clinically safe monoamine stabilizer (-)-OSU6162 (OSU6162) restores dopaminergic dysfunction in long-term alcohol-drinking rats and shows promise as a novel treatment for alcohol use disorder. "
01/01/2019 - "The monoamine stabilizer (-)-OSU6162 (OSU6162) has the ability to stabilize dopamine activity depending on the prevailing dopaminergic tone and may therefore normalize the dopaminergic transmission regulating both alcohol use disorder and impulsivity. "

10/01/2014 - "Tolerability and efficacy of the monoaminergic stabilizer (-)-OSU6162 (PNU-96391A) in Huntington's disease: a double-blind cross-over study."
10/01/2014 - "To evaluate the safety (primary objective) and efficacy (secondary objective) of (-)-OSU6162 in Huntington's disease (HD). "
10/22/1999 - "Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease."
11/01/2011 - "(-)-OSU6162 has promise for treating Parkinson's disease, Huntington's disease and schizophrenia. "
11/01/2010 - "BACKGROUND AND PURPOSE; The two phenylpiperidines, OSU6162 and ACR16, have been proposed as novel drugs for the treatment of brain disorders, including schizophrenia and Huntington's disease, because of their putative dopamine stabilizing effects. "